M6P Therapeutics KOL Webinar on Lysosomal Storage Disorders
|DATE:||July 28, 2021|
|TIME:||12:00 AM EDT|
About The Event
The webinar will feature a fireside chat with Key Opinion Leaders (KOLs) Gregory Enns, M.D. (Lucile Salter Packard Children’s Hospital Stanford School of Medicine) and Mark S. Sands, Ph.D. (Departments of Medicine and Genetics at Washington University School of Medicine) who will discuss the current treatment landscape and unmet medical needs in Lysosomal Storage Disorders (LSDs), including Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidoses and mucolipidoses. LSDs are a family of approximately 50 rare, genetic, and life-threatening diseases characterized by a deficiency in a specific lysosomal enzyme.
The event will also feature an update from the M6PT management team on their Recombinant Enzyme and Gene Therapy technology platform for the treatment of LSDs. The Company plans to initiate its first clinical program in 2022.
Dr. Enns, Dr. Sands, and M6PT management will also take questions from the audience.